XtalPi (QUANTUMPH-P, Stock Code: 2228.HK) today announced a licensing agreement between Ailux Biologics, a division of XtalPi, and Janssen Biotech, Inc., a Johnson & Johnson company, granting access to its proprietary XtalFold™ AI platform for biologics discovery and engineering. Facilitated by Johnson & Johnson Innovation, this partnership marks a significant step in accelerating the development of next-generation therapeutics.
Unlocking the Potential of Biologics
XtalFold™, an AI-powered software platform, revolutionizes biologics R&D by Rapid Structural Insights providing accurate 3D visualization of complex biomolecular interactions, such as antibody-antigen interfaces and reduces discovery timelines from months to days, enabling faster progression from concept to clinic. Its performance has been validated in 30+ internal and external projects, with applications spanning antigen design, epitope mapping, affinity maturation, pH sensitivity optimization, and bispecific antibody engineering.
Industry-Leading Capabilities
In rigorous benchmarking, XtalFold™ has demonstrated superior performance in modeling challenging regions critical to biologics efficacy. Its ability to predict and optimize molecular interactions has set a new standard for AI-driven drug discovery.
“Biologics are intricate machines operating in three-dimensional space. XtalFold™ allows us to visualize and design these molecules with unprecedented speed and precision—a process that traditionally took months. We’re thrilled to share this transformative technology with Janssen Biotech, empowering them to accelerate the development of life-changing therapies.”
– Dr. Yi Li, Vice President of XtalPi and Head of Ailux Biologics
About Ailux Biologics
Ailux Biologics is a division of XtalPi dedicated to the innovation in large molecule drug discovery. With a team of around 100 experts, Ailux has established a state-of-the-art biologics discovery lab, a proprietary database purpose-built for AI (AtlaX™) and a trio of AI platforms, including a structure modeling suite (XtalFold™), a generative large language model for proteins (XenProT™) and a predictive AI suite for biologics (Xentient™). Ailux partners with pharma and biotech companies to accelerate their biologics programs with AI-powered, lab-validated solutions.